Compare NKTX & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKTX | OCCI |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 139.4M |
| IPO Year | 2020 | N/A |
| Metric | NKTX | OCCI |
|---|---|---|
| Price | $2.09 | $5.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $13.25 | N/A |
| AVG Volume (30 Days) | ★ 708.2K | 115.8K |
| Earning Date | 11-10-2025 | 12-11-2023 |
| Dividend Yield | N/A | ★ 24.32% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $5.47 |
| 52 Week High | $2.74 | $10.15 |
| Indicator | NKTX | OCCI |
|---|---|---|
| Relative Strength Index (RSI) | 69.68 | 60.96 |
| Support Level | $1.79 | $4.50 |
| Resistance Level | $2.22 | $4.82 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 75.73 | 87.50 |
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.